Latest Interviews
Showing 1–2 of 2 transcripts.
Clear all filters- Bank of America25 min
GLP-1s are shrinking some appetites; broader use poses a prickly challenge
Peter Galbo, Jason Gerberry, TJ Thornton
As of May 2026, the U.S. GLP-1 market has reached 10 million treated patients and $28 billion in revenue while facing a deflationary pricing cycle driven by Medicare agreements and an upcoming surge of generic semaglutide competitors. This therapeutic expansion is displacing packaged food volume in snack and alcohol categories, forcing large-cap pharmaceutical firms to trade at depressed multiples as the market nears U.S. saturation and pivots toward international growth. Future value will increasingly depend on next-generation formulations targeting muscle preservation and adherence rates, with analysts forecasting a shift where international sales eventually comprise more than half of total category revenue.
- Bank of America27 min
Why we believe AI reshapes work more so than it reduces overall payrolls
Benson Wu, Nick Stenner, TJ Thornton
BofA Global Research contends that generative AI will primarily augment human labor and reshape specific tasks rather than cause mass job elimination, with only 2.3% of global roles facing high automation potential while 13% offer significant augmentation opportunities. The report projects a shift toward new AI specialist roles, hybrid professionals, and human-centric services in sectors like healthcare, noting that advanced economies possess the infrastructure to adapt despite risks of capital concentration and entry-level wage dispersion. Macroeconomic analysis suggests these productivity gains will be disinflationary over the long term, potentially allowing central banks flexibility on interest rates even as transition costs and uneven gains create short-term policy complexities.